论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Zhao Z, Song ZJ, Wang XW, Sun HF, Yang XM, Yuan Y, Yu P
Received 6 March 2017
Accepted for publication 13 June 2017
Published 21 August 2017 Volume 2017:10 Pages 4129—4133
DOI https://doi.org/10.2147/OTT.S136297
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Dr Tohru Yamada
摘要:ROS1 融合在非小细胞肺癌中是一种常见的基因变异。克唑替尼是一种间变性淋巴瘤激酶抑制剂,已经被证明在对携带有 ROS1 融合的肺癌的案例中有效。本文报道了一例携带有不同于常见的两种 SLC34A2-ROS1 融合变异类型的新变异患者同样对克唑替尼有效的案例。按照克唑替尼的说明书服药后,这名患者的身体总体好转;主要病变缩小;淋巴结转移消失;新陈代谢也恢复正常。
关键词:SLC34A2-ROS1 融合;克唑替尼;肺腺癌;二代测序
摘要视频链接:Crizotinib treatment in lung
adenocarcinoma patient with ROS1 fusion
